These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 19335743)

  • 1. Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma.
    Shiwen X; Leask A; Abraham DJ; Fonseca C
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():19-26. PubMed ID: 19335743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characteristic of the endogenous peptides--endothelins and their role in the connective tissue fibrosis].
    Garncarczyk A; Jurzak M; Gojniczek K
    Wiad Lek; 2008; 61(4-6):126-34. PubMed ID: 18939363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of endothelin and endothelin receptor antagonists in renal disease.
    Neuhofer W; Pittrow D
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():78-88. PubMed ID: 16919017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin receptor antagonism--new perspectives in the treatment of systemic sclerosis.
    Kowal-Bielecka O; Sierakowski S
    Rocz Akad Med Bialymst; 2005; 50 Suppl 1():291-3. PubMed ID: 16119689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?
    Abraham D
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v8-9. PubMed ID: 18784153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease.
    Abraham DJ; Vancheeswaran R; Dashwood MR; Rajkumar VS; Pantelides P; Xu SW; du Bois RM; Black CM
    Am J Pathol; 1997 Sep; 151(3):831-41. PubMed ID: 9284832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence.
    Neuhofer W; Pittrow D
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():50-67. PubMed ID: 19335747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. At the heart of tissue: endothelin system and end-organ damage.
    Iglarz M; Clozel M
    Clin Sci (Lond); 2010 Aug; 119(11):453-63. PubMed ID: 20712600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis.
    Leask A
    Pharmacol Res; 2011 Jun; 63(6):502-3. PubMed ID: 21315153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
    Jacobs A; Preston IR; Gomberg-Maitland M
    Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scleroderma: from cell and molecular mechanisms to disease models.
    Abraham DJ; Varga J
    Trends Immunol; 2005 Nov; 26(11):587-95. PubMed ID: 16168711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies.
    Davie NJ; Schermuly RT; Weissmann N; Grimminger F; Ghofrani HA
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():38-49. PubMed ID: 19335746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Takehara K; Tedder TF
    Mol Immunol; 2004 Nov; 41(12):1123-33. PubMed ID: 15482848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin--role in vascular disease.
    Abraham D; Dashwood M
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v23-4. PubMed ID: 18784133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of endothelin in connective tissue diseases.
    Sticherling M
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii8-10. PubMed ID: 16987839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through up-regulation of endothelin receptor A.
    Chrysanthopoulou A; Mitroulis I; Kambas K; Skendros P; Kourtzelis I; Vradelis S; Kolios G; Aslanidis S; Doumas M; Ritis K
    Arthritis Rheum; 2011 Nov; 63(11):3586-97. PubMed ID: 21834070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future targets in the management of systemic sclerosis.
    Tyndall A; Matucci-Cerinic M; Müller-Ladner U
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii49-53. PubMed ID: 19487225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targets in systemic sclerosis.
    Denton CP
    Arthritis Res Ther; 2007; 9 Suppl 2(Suppl 2):S6. PubMed ID: 17767744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired growth response to endothelin-1 in scleroderma fibroblasts.
    Kikuchi K; Kadono T; Sato S; Tamaki K; Takehara K
    Biochem Biophys Res Commun; 1995 Feb; 207(2):829-38. PubMed ID: 7864878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.
    Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Dermatol Sci; 2005 Jul; 39(1):1-7. PubMed ID: 15885984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.